Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | GLA | P06280 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | AR | P10275 | 6/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TNKS2 | Q9H2K2 | 8/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | TNKS | O95271 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14176757 | 0.88 | KDM4E (0.53) | KDM4EGAAGLAHPGDALDH1A1 | |
| SCHEMBL14369937 | 0.79 | KDM4E (0.53) | KDM4EGAAGLAHPGDALDH1A1 | |
| SCHEMBL15159310 | 0.79 | AR (0.65) | KDM4EGAAGLAHPGDALDH1A1 | |
| SCHEMBL14399200 | 0.77 | HPGD (0.63) | KDM4EGAAGLAHPGDALDH1A1 | |
| SCHEMBL20858926 | 0.75 | KDM4E (0.51) | KDM4EGAAGLAHPGDALDH1A1 | |
| SCHEMBL18486021 | 0.75 | KDM4E (0.42) | KDM4EGAAGLAHPGDALDH1A1 | |
| SCHEMBL7923976 | 0.74 | KDM4E (0.53) | KDM4EGAAGLAHPGDALDH1A1 | |
| SCHEMBL10056890 | 0.74 | KDM4E (0.64) | KDM4EGAAGLAHPGDALDH1A1 | |
| SCHEMBL31331891 | 0.73 | TNKS2 (0.66) | KDM4EGAAGLAHPGDALDH1A1 | |
| SCHEMBL23130687 | 0.72 | ALDH1A1 (0.65) | KDM4EGAAGLAHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080138817-A1 | Novel Functional Peptide Nucleic Acid Monomer and Process for Producing the Same | CREDIA JAPAN CO., LTD. (JP) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080138817-A1 | Novel Functional Peptide Nucleic Acid Monomer and Process for Producing the Same | NSUN3, RNGTT, NSUN2 | KDM4E 4577/4885GAA 3843/4885GLA 4466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.